Abstract: Provided is a control method for a system for determining a lesion obtained via real-time image. The control method comprises: an endoscope device obtaining a stomach endoscopy image; the endoscope device transmitting the obtained stomach endoscopy image to a server; the server determining a lesion included in the stomach endoscopy image, by inputting the stomach endoscopy image into a first artificial intelligence model; when it is determined that a lesion is detected in the stomach endoscopy image, the server obtaining an image including the lesion and transmitting the image to a database of the server; the server determining the type of the lesion included in the image, by inputting the image into a second artificial intelligence model; and when it is determined that a lesion is detected in the stomach endoscopy image, a display device displaying a UI for guiding the location of the lesion in the stomach endoscopy image.

Abstract: The present invention relates to a technology for diagnosing dizziness by testing eye movement (motion), and more particularly, to a method and apparatus for diagnosing dizziness through eye movement measurement based on virtual reality capable of utilizing a commercialized virtual reality device to measure and test eye movement and transmit resultant data, measuring optokinetic nystagmus through movement of various gazing points (objects) generated in virtual reality, and diagnosing dizziness through the measurement, a recording medium storing a program for realizing the same, and a computer program stored in the recording medium.

Abstract: Provided is a control method for a system for determining a lesion obtained via a real-time image. The control method comprises the steps of: an endoscope device obtaining a stomach endoscopy image; the endoscope device transmitting the obtained stomach endoscopy image to a server; the server determining a lesion included in the stomach endoscopy image, by inputting the stomach endoscopy image into a first artificial intelligence model; when it is determined that a lesion is detected in the stomach endoscopy image, the server obtaining an image including the lesion and transmitting the image to a database of the server; the server determining the type of the lesion included in the image, by inputting the image into a second artificial intelligence model; and when it is determined that a lesion is detected in the stomach endoscopy image, a display device displaying a UI for guiding the location of the lesion in the stomach endoscopy image.

Abstract: The present disclosure relates to the composition and process for the production of an ultra-strong, biocompatible, electroconductive, and stretchable hydrogel, which comprises: a step (a) of physical or chemical modification of natural polymers e.g., preparation of silk nanofiber and double methacrylation of gelatin; a step (b) of graphene oxide (GO) carboxylation; a step (c) of carbodiimidation between methacrylated natural polymers of step (a) and carboxylated GO of step (b); and a step (d) of three dimensional (3D) bioprinting of step (c) with/without silk nanofiber. It was found that these steps in this disclosure give rise to a biocompatible hydrogel with high mechanical strength in the range of load-bearing soft tissue such as tendon and heart as opposed to conventional hydrogels.

Abstract: A training system for sound directional discrimination ability includes: a speaker that is located in an angle range determined left or right in front of a human dummy or disposed in front of a subject and generates a sound directional training sound multiple times; a microphone which is worn on each of both ears of a human dummy or the subject and obtains the training sound; a training sound reproduction unit for reproducing at least a part of the obtained training sound for each of the configuration angles; a response information determination unit for providing the subject with multiple visual targets for each of the configuration angles and determining whether the subject has selected a correct response visual target among the multiple visual targets; and a level control unit for selecting at least one angle among the configuration angles.

Abstract: A purification device is provided. The purification device includes: an injection channel having an inlet provided on one end thereof; a purification channel and a discharge channel which branch off from the other end of the injection channel via a mesh part, and the remaining substance to be purified is discharged through the discharge channel; an ion-selective membrane contacting at least one side of the mesh part; and a buffer part arranged on the other side of the ion-selective membrane which is in contact with the mesh part, wherein the mesh part has an ion-selective coating layer formed on the surface thereof, and when an electric field is applied, an ion concentration polarization phenomenon occurs to the other end of the injection channel and to the adjacent portion of the mesh part, whereby an ion depletion zone is formed.

Abstract: The present invention relates to a vaccine composition comprising cyclic peptides of the present invention, antibodies to cyclic peptides, or an anticancer composition comprising them, and the vaccine composition of the present invention exhibit an inhibitory activity for metastasis of cancer. In addition, the antibodies of the present invention bind to the tumor-specific antigen TM4SF5 with high affinity, and significantly inhibit the growth, metastasis and invasion of cancer cells expressing the tumor-specific antigen TM4SF5, and thus can be used for diagnosis, prevention or treatment of various cancers expressing TM4SF5.

Abstract: Provided are a method for preventing or treating obesity by using a composition including an inhibitor of expression of the Hoga1 gene or an inhibitor of activity of the Hoga1 protein as an active ingredient, and a method of screening a preventive or therapeutic agent for obesity by using the composition.

Abstract: The present invention relates to an eye movement measurement method including the steps of: (a) presenting standardized nystagmus test items and receiving am image of an eye in accordance with the standardized nystagmus test items; (b) recognizing a pupil and an iris from the image of the eye; (c) calculating amounts of horizontal and vertical changes of the pupil and an amount of torsional movement of the iris; (d) determining change values and orientations for three axis directions of the eye on the basis of the amounts of the horizontal and vertical changes of the pupil and the amount of the torsional movement of the iris; and (e) generating a diagnosis result for vertigo through deep learning modeling on the basis of the change values and orientations of the three axis directions of the eye.

Abstract: Provided is a portable urea sensor which can be used under a flow condition by using a porous polytetrafluoroethylene (PTFE) membrane coated with parylene-A, which is parylene functionalized with an amine by vacuum deposition. To produce a specific electrochemical sensor signal from urea, urease, which is an enzyme hydrolyzing urea, is immobilized to a parylene-A-coated PTFE membrane by chemical crosslinking using glutaraldehyde. The urea-immobilized membranes are assembled in a polydimethylsiloxane (PDMS) fluid chamber, and a screen-printed carbon 3-electrode system is used. The success of the urease immobilization process is confirmed using scanning electronmicroscopy (SEM) and Fourier-transform infrared (FTIR) spectroscopy. The optimal concentration of urease to be immobilized to the parylene-A-coated PTFE membrane is determined to be 48 mg/mL, and the optimal number of the membranes in the PDMS chamber is determined to be 8.

Abstract: The present invention relates to a vaccine composition comprising cyclic peptides of the present invention, antibodies to cyclic peptides, or an anticancer composition comprising them, and the vaccine composition of the present invention exhibit an inhibitory activity for metastasis of cancer. In addition, the antibodies of the present invention bind to the tumor-specific antigen TM4SF5 with high affinity, and significantly inhibit the growth, metastasis and invasion of cancer cells expressing the tumor-specific antigen TM4SF5, and thus can be used for diagnosis, prevention or treatment of various cancers expressing TM4SF5.

Abstract: A beamforming device, an ultrasonic imaging device, and a beamforming method, which allow a simple spatial smoothing operation, are disclosed. A beamforming device according to an embodiment of the present invention comprises: a spatial smoothing unit for transforming a received signal into another space, using a transformation function configured by low frequency components, calculating a transformed signal by a spatial smoothing operation using a transformation function in a transformation space, and estimating an averaged spatial covariance matrix; a weighted value operation unit for operating a weighted value of the transformed signal from the averaged spatial covariance matrix which has been estimated by the spatial smoothing operation; and a synthesis unit for generating a beam signal, using the transformed signal and the weighted value of the transformed signal.

Abstract: Provided are a method for preventing or treating obesity by using a composition including an inhibitor of expression of the Hoga1 gene or an inhibitor of activity of the Hoga1 protein as an active ingredient, and a method of screening a preventive or therapeutic agent for obesity by using the composition.

Abstract: An image processing module includes an input unit, a weight operator, and a synthesizer. The input unit is configured to receive a plurality of input signals of a plurality of channels. The weight operator is configured to calculate at least one weight to be applied to each channel based on at least one converted signal. The at least one converted signal is acquired by converting at least one input signal among the plurality of input signals of each channel, or by converting a synthesized input signal of the plurality of input signals of each channel. The synthesizer is configured to synthesize the plurality of input signals of the plurality of channels using the weight.

Abstract: A beamforming module includes a conversion unit configured to convert an input signal to generate a converted signal using at least one conversion function, a weight calculator configured to calculate a converted signal weight as a weight for the converted signal, and a synthesizer configured to generate a result signal using the converted signal and the converted signal weight.

Abstract: The present invention provides an antibody or antigen binding fragment thereof, that binds to TM4SF5, and uses thereof. The antibody of this invention inhibits the growth, metastasis and invasion of cancer cells expressing TM4SF5 by binding to a tumor-specific antigen, TM4SF5, with high affinity, and therefore can be used to diagnose, prevent or treat various cancers expressing TM4SF5.

Abstract: A beamforming apparatus includes a storage for storing a plurality of basis vectors obtained from a beamforming coefficient of a previously-measured echo signal; a weight calculator for calculating a weight to be applied to an echo signal reflected from a target; and a synthesizer for applying the weight to the echo signal reflected from the target and synthesizing signals to which the weight is applied.

Abstract: The present invention relates to a composition for enhancing an immune response, an epitope having immunogenicity, screening and preparing method thereof, a antibody to peptide antigen and screening and preparing method thereof. The composition of the present invention may be effectively used for preventing or treating diverse immune-deficiency diseases such as cancer, influenza virus, hepatitis C virus and RSV (respiratory syncytial virus) by enhancing immune responses.

Abstract: Provided is a pharmaceutical composition for treating corneal endothelium wounds, the composition including angiogenin as an effective ingredient. The present invention relates to a new topical therapeutic use of angiogenin for treatment of corneal endothelium wounds, wherein the angiogenin that is generally known to be involved in angiogenesis activates a PI3K/Akt/eNOS pathway thereof in ocular corneal endothelium to increase migration and proliferation of corneal endothelial cells that are not capable of self-proliferation and to promote prevention and treatment of corneal endothelial cell wounds.

Abstract: Disclosed is a treatment for ophthalmic diseases, more specifically, a pharmaceutical composition for treating ophthalmic diseases including a fusion protein of FK506 binding protein capable of penetrating into the ocular tissue as an active ingredient.